Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 235

The DOI matches its Crossref record.

Randomized Selection Design Trial Evaluating CD8+-Enriched Versus Unselected Tumor-Infiltrating Lymphocytes for Adoptive Cell Therapy for Patients With Melanoma

Open access
Dudley, Mark E., Gross, Colin A., Somerville, Robert P.T., Hong, Young, Schaub, Nicholas P., Rosati, Shannon F., White, Donald E., Nathan, Debbie, Restifo, Nicholas P., Steinberg, Seth M., Wunderlich, John R., Kammula, Udai S., Sherry, Richard M., Yang, James C., Phan, Giao Q., Hughes, Marybeth S., Laurencot, Carolyn M., Rosenberg, Steven A.·2013·Journal of Clinical Oncology

Abstract

Purpose: Adoptive cell therapy (ACT) with autologous tumor-infiltrating lymphocytes (TILs) and high-dose interleukin-2 (IL-2) administered to lymphodepleted patients with melanoma can cause durable tumor regressions. The optimal TIL product for ACT is unknown. Patients and Methods: Patients with metastatic melanoma were prospectively assigned to receive unselected young TILs versus CD8+-enriched TILs. All patients received lymphodepleting chemotherapy and high-dose IL-2 therapy and were assessed for response, toxicity, survival, and immunologic end points. Results: Thirty-four patients received unselected young TILs with a median of 8.0% CD4+lymphocytes, and 35 patients received CD8+-enriched TILs with a median of 0.3% CD4+lymphocytes. One month after TIL infusion, patients who received CD8+-enriched TILs had significantly fewer CD4+peripheral blood lymphocytes (P = .01). Twelve patients responded to therapy with unselected young TILs (according to Response Evaluation Criteria in Solid Tumors [RECIST]), and seven patients responded to CD8+-enriched TILs (35% v 20%; not significant). Retrospective studies showed a significant association between response to treatment and interferon gamma secretion by the infused TILs in response to autologous tumor (P = .04), and in the subgroup of patients who received TILs from subcutaneous tumors, eight of 15 patients receiving unselected young TILs responded but none of eight patients receiving CD8+-enriched TILs responded. Conclusion: A randomized selection design trial was feasible for improving individualized TIL therapy. Since the evidence indicates that CD8+-enriched TILs are not more potent therapeutically and they are more laborious to prepare, future studies should focus on unselected young TILs.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2012.46.6441

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 235

Metadata

Authors
Dudley, M. E., Gross, C. A., Somerville, R. P. T., Hong, Y., Schaub, N. P., Rosati, S. F., White, D. E., Nathan, D., Restifo, N. P., Steinberg, S. M., Wunderlich, J. R., Kammula, U. S., Sherry, R. M., Yang, J. C., Phan, G. Q., Hughes, M. S., Laurencot, C. M., & Rosenberg, S. A.
Venue
Journal of Clinical Oncology
Published
2013-06-10
Volume
31
Issue
17
Pages
2152-2159
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W1965029629
Cited by
235
References
0
FWCI
13.75
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Randomized Selection Design Trial Evaluating CD8+-Enriched Versus Unselected Tumor-Infiltrating Lymphocytes for Adoptive Cell Therapy for Patients With Melanoma. https://app.cochat.ai/papers/10.1200/jco.2012.46.6441
The paper
Dudley, M. E., Gross, C. A., Somerville, R. P. T., Hong, Y., Schaub, N. P., Rosati, S. F., White, D. E., Nathan, D., Restifo, N. P., Steinberg, S. M., Wunderlich, J. R., Kammula, U. S., Sherry, R. M., Yang, J. C., Phan, G. Q., Hughes, M. S., Laurencot, C. M., & Rosenberg, S. A. (2013). Randomized Selection Design Trial Evaluating CD8+-Enriched Versus Unselected Tumor-Infiltrating Lymphocytes for Adoptive Cell Therapy for Patients With Melanoma. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2012.46.6441

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.